Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
Anorexia and weight loss are devastating complications in late-stage cancer patients and is
strongly associated with mortality in these patients. Activation of Ghrelin receptors have
been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity
and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced
anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the
treatment of cancer patients with anorexia and weight loss.